PP405 Research for Androgenetic Alopecia

In androgenetic alopecia, follicles typically shrink over successive cycles: the hair they produce becomes finer and shorter, and the follicles spend more time in dormancy. Critically, in much of the affected scalp the follicular structure — including its stem-cell compartment — persists. That persistence is the entire basis of reactivation-directed research: dormant is not absent.[1][10]

The developer of PP405 frames its programme the same way: balding scalp is described as retaining dormant follicles and stem cells whose metabolic state may be researchable as a reversible condition. The framing is consistent with published follicle biology — and remains a hypothesis under clinical investigation.[5]

Established pattern-loss pharmacology acts mainly on hormonal signalling. The PP405 research direction is different: it targets the metabolic switch inside the follicle stem cell itself — pyruvate handling at the mitochondrial pyruvate carrier — on the basis of peer-reviewed mouse research linking that switch to stem-cell activation and hair-cycle entry.[2]

Notably, the preclinical work extended beyond ordinary cycling: in mouse models of alopecia driven by age, repeated chemotherapy and stress, pyruvate-oxidation inhibition still accelerated the hair cycle, with histologically normal follicles forming in those models. Animal models are not human alopecia — but they are the reason the metabolic angle is taken seriously.[3]

The completed human study, NCT06393452, enrolled 78 adults with androgenetic alopecia in a randomized, double-blind, vehicle-controlled Phase 2a design. The developer reports met tolerability and pharmacokinetic endpoints with no detectable systemic absorption, plus an exploratory week-8 density signal in a subgroup of men with more advanced loss — company-reported findings awaiting peer-reviewed publication.[4][5]

A $120M Series B announced on 2025-10-15 is intended to fund Phase 3 trials in androgenetic alopecia from 2026. The WHO INN programme’s 2026 proposed name for the compound — suvomipic, classed as a mitochondrial pyruvate carrier inhibitor — places the mechanism in the international nomenclature record.[6][9]